These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 26888822

  • 1. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
    Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X.
    BMJ; 2016 Feb 17; 352():i610. PubMed ID: 26888822
    [Abstract] [Full Text] [Related]

  • 2. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X.
    BMJ; 2014 Apr 15; 348():g2366. PubMed ID: 24736555
    [Abstract] [Full Text] [Related]

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B, Sonne DP, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2017 May 10; 5(5):CD012204. PubMed ID: 28489279
    [Abstract] [Full Text] [Related]

  • 4. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
    Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X.
    BMJ; 2017 Jun 08; 357():j2499. PubMed ID: 28596247
    [Abstract] [Full Text] [Related]

  • 5. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S.
    Cochrane Database Syst Rev; 2017 Feb 27; 2(2):CD009966. PubMed ID: 28238223
    [Abstract] [Full Text] [Related]

  • 6. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
    Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO, Wong E, Sohani ZN, Bala MM, Rios LP, Malaga G, Ebrahim S, Shen J, Zhang L, Zhao P, Chen Q, Wang Y, Guyatt GH, Sun X.
    BMC Cardiovasc Disord; 2016 May 11; 16():91. PubMed ID: 27169565
    [Abstract] [Full Text] [Related]

  • 7. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K, Gräber S.
    Diabetes Obes Metab; 2012 Dec 11; 14(12):1061-72. PubMed ID: 22519906
    [Abstract] [Full Text] [Related]

  • 8. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ.
    Circ Heart Fail; 2017 Sep 11; 10(9):. PubMed ID: 28899989
    [Abstract] [Full Text] [Related]

  • 9. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P.
    Clin Ther; 2014 Dec 01; 36(12):2072-2079. PubMed ID: 25453730
    [Abstract] [Full Text] [Related]

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 11. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr 01; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

  • 12. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.
    BMJ; 2012 Mar 12; 344():e1369. PubMed ID: 22411919
    [Abstract] [Full Text] [Related]

  • 13. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, Green JB, Ruff CT, Sabatine MS.
    Clin Cardiol; 2022 Jul 12; 45(7):794-801. PubMed ID: 35715946
    [Abstract] [Full Text] [Related]

  • 14. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
    Guo WQ, Li L, Su Q, Dai WR, Ye ZL.
    Value Health; 2017 Dec 12; 20(10):1427-1430. PubMed ID: 29241903
    [Abstract] [Full Text] [Related]

  • 15. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
    Sano M.
    J Cardiol; 2019 Jan 12; 73(1):28-32. PubMed ID: 30318179
    [Abstract] [Full Text] [Related]

  • 16. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A.
    BMJ; 2016 May 03; 353():i2231. PubMed ID: 27142267
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.
    Xu S, Zhang X, Tang L, Zhang F, Tong N.
    Postgrad Med; 2017 Mar 03; 129(2):205-215. PubMed ID: 27813442
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E, Monami M.
    Adv Ther; 2017 Jan 03; 34(1):1-40. PubMed ID: 27844335
    [Abstract] [Full Text] [Related]

  • 19. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W.
    Diabetes Metab Res Rev; 2014 Mar 03; 30(3):241-56. PubMed ID: 24123720
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
    Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, Wayangankar SA, Bavry AA.
    Am J Cardiovasc Drugs; 2017 Apr 03; 17(2):143-155. PubMed ID: 27873238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.